NASDAQ:CODX Co-Diagnostics (CODX) Stock Price, News & Analysis $0.20 -0.03 (-12.85%) Closing price 04:00 PM EasternExtended Trading$0.19 -0.01 (-2.55%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsOwnershipSEC Filings About Co-Diagnostics Stock (NASDAQ:CODX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Co-Diagnostics alerts:Sign Up Key Stats Today's Range$0.17▼$0.2150-Day Range$0.22▼$1.2552-Week Range$0.17▼$13.54Volume970,616 shsAverage Volume2.58 million shsMarket Capitalization$2.06 millionP/E RatioN/ADividend YieldN/APrice Target$45.00Consensus RatingHold Company Overview Co-Diagnostics, Inc. is a molecular diagnostics company that develops technologies and tests for detecting infectious diseases. Based in Salt Lake City, Utah, the company’s work centers on its proprietary CoPrimer technology, used to design assays for polymerase chain reaction (PCR) testing. Its products include PCR-based diagnostic tests and related instruments, including the Co-Dx PCR platform. The company has developed tests for a range of infectious diseases, with product availability and regulatory status varying by market. Co-Diagnostics was established in 2013 and serves customers in the United States and international markets through commercial and distribution channels.AI Generated. May Contain Errors. Read More Co-Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreCODX MarketRank™: 2.093439363815 of 5 starsCo-Diagnostics scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingCo-Diagnostics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCo-Diagnostics has a consensus price target of $45.00, representing about 22,976.9% upside from its current price of $0.20.Amount of Analyst CoverageCo-Diagnostics has only been the subject of 1 research reports in the past 90 days.Read more about Co-Diagnostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Co-Diagnostics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Co-Diagnostics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCo-Diagnostics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.52% of the float of Co-Diagnostics has been sold short.Short Interest Ratio / Days to CoverCo-Diagnostics has a short interest ratio ("days to cover") of 2.24, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Co-Diagnostics has recently increased by 49.51%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCo-Diagnostics does not currently pay a dividend.Dividend GrowthCo-Diagnostics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.63 News SentimentCo-Diagnostics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Co-Diagnostics this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for CODX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Co-Diagnostics to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Co-Diagnostics insiders have not sold or bought any company stock.Percentage Held by Insiders1.70% of the stock of Co-Diagnostics is held by insiders.Percentage Held by Institutions14.99% of the stock of Co-Diagnostics is held by institutions.Read more about Co-Diagnostics' insider trading history. Receive CODX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CODX Stock News HeadlinesCo-Diagnostics Receives Logix Smart® ZDC Test Order from Peru Distributor as Dengue Cases Rise and Exhibits at MEDICA 2026 in DüsseldorfNovember 17 at 10:34 AM | finance.yahoo.comCo-Diagnostics, Inc. (CODX) Q3 Sales IncreaseNovember 10, 2026 | rttnews.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 17 at 1:00 AM | Profits Run (Ad)Co-Diagnostics Reports Third Quarter 2026 Financial ResultsNovember 10, 2026 | prnewswire.comCo-Diagnostics Announces Updated Third Quarter 2026 Earnings Release Date and WebcastNovember 5, 2026 | prnewswire.comCo-Diagnostics to Participate in Three Global Tuberculosis Events in November as CoSara Advances Toward Anticipated India LaunchNovember 5, 2026 | prnewswire.comCo-Diagnostics Announces Third Quarter 2026 Earnings Release Date and WebcastOctober 29, 2026 | prnewswire.comCo-Diagnostics' Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara's SARAGENE® TestOctober 29, 2026 | prnewswire.comSee More Headlines CODX Stock Analysis - Frequently Asked Questions How have CODX shares performed this year? Co-Diagnostics' stock was trading at $5.56 at the beginning of 2026. Since then, CODX shares have decreased by 96.5% and is now trading at $0.1950. How were Co-Diagnostics' earnings last quarter? Co-Diagnostics, Inc. (NASDAQ:CODX) posted its earnings results on Tuesday, November, 10th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.25) by $0.24. The company earned $282.88 thousand during the quarter, compared to the consensus estimate of $169 thousand. Co-Diagnostics had a negative net margin of 5,530.54% and a negative trailing twelve-month return on equity of 322.92%. Read the conference call transcript. When did Co-Diagnostics' stock split? Shares of Co-Diagnostics reverse split before market open on Friday, January 2nd 2026.The 1-30 reverse split was announced on Tuesday, December 30th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, December 31st 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Co-Diagnostics IPO? Co-Diagnostics (CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO. How do I buy shares of Co-Diagnostics? Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Co-Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), NIO (NIO) and Novavax (NVAX). Company Calendar Last Earnings11/10/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (12m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CODX's financial health is in the Red zone, according to TradeSmith. CODX has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CODX CIK1692415 Webwww.codiagnostics.com Phone(801) 438-1036FaxN/AEmployees115Year Founded2013Price Target and Rating Average Price Target for Co-Diagnostics$45.00 High Price Target$45.00 Low Price Target$45.00 Potential Upside/Downside+22,859.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($10.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$46.90 million Net Margins-5,530.54% Pretax Margin-5,583.55% Return on Equity-322.92% Return on Assets-251.11% Debt Debt-to-Equity RatioN/A Current Ratio0.77 Quick Ratio1.52 Sales & Book Value Annual Sales$620 thousand Price / Sales3.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / Book0.22Miscellaneous Outstanding Shares10,510,000Free Float10,333,000Market Cap$2.06 million OptionableNo Data Beta3.15 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:CODX) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBitcoin's problem is its own sizeBitcoin is trading near $60,000. For your Bitcoin position to double from here, roughly $1.5 trillion in new m...Crypto 101 Media | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Co-Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Co-Diagnostics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.